All In Biotech

Drug Trial Radar · NCT06229288

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward: a Non-inferiority Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

326

Planned (sponsor's estimate)

Start

Apr 25, 2024

Primary completion

May 25, 2027

Study completion May 25, 2027

Sponsor

Lead sponsor
Nantes University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions. In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies. Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.

Conditions

  • Community-acquired Pneumonia

Interventions

  • AmoxicillinDrug

    Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily). Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)

  • Amoxicillin/clavulanateDrug

    Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Non-inferiorityTime frame: Day 30 after inclusion (=Day 1)

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Chu Angers

    Angers, France · Recruiting

  • CHU Angers

    Angers, France · Recruiting

  • CHU Avicenne AP-HP

    Bobigny, France · Recruiting

  • CHU Avicenne AP-HP

    Bobigny, France · Recruiting

  • CHRU Brest

    Brest, France · Recruiting

  • CHRU Brest

    Brest, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • CHD Vendée

    La Roche-sur-Yon, France · Recruiting

  • CHU Grenoble-Alpes

    La Tronche, France · Recruiting

  • CHU Grenoble-Alpes

    La Tronche, France · Recruiting

  • Assistance Publique Hopitaux De Marseille

    Marseille, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • CH Perigueux

    Périgueux, France · Recruiting

  • CH Saint-Nazaire

    Saint-Nazaire, France · Recruiting

  • CH Saint-Nazaire

    Saint-Nazaire, France · Recruiting

  • CHRU - TOULOUSE Hôpital Purpan

    Toulouse, France · Recruiting

  • CHRU - TOULOUSE Hôpital Purpan

    Toulouse, France · Recruiting

  • CHRU TOULOUSE - Hôpital Rangueuil

    Toulouse, France · Recruiting

  • Centre Hospitalier Bretagne Atlantique

    Vannes, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.